Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Bol. latinoam. Caribe plantas med. aromát ; 13(6): 566-574, nov.2014. ilus, tab
Artículo en Inglés | LILACS | ID: lil-795827

RESUMEN

The synthesis of new isomeric ellipticine quinones 3a-c and their in vitro antiproliferative activities on cancer cell lines is reported. The designed N-heterocyclic quinones 3a-c were synthesized through a three step sequence which involves: a) one-pot preparation of 4-methoxycarbonyl-3,4-dimethylisoquinoline-5,8-quinone 1 from 2,5-dihydroxyacetophenone, methyl aminocrotonate and silver (II) oxide; b) regioselective amination of 1 with arylamines to give aminoquinones 2a-c and c) palladium-catalyzed intramolecular oxidative coupling of 7-aminoisoquinoline-5,8-quinones 2a-c. The in vitro antiproliferative activity of the new angular quinones was evaluated againts one normal cell line (lung fibroblasts) and gastric, lung and bladder cancer cell lines in 72-h drug exposure assays. The new compounds displayed similar or higher antiproliferative activity with respect to their quinone precursors 2a-c. The isomeric ellipticine quinone 2b appears as the more active member on bladder cancer cell line (IC50: 2.4 uM), comparable to etoposide used as anticancer reference drug...


Se describe la síntesis de las nuevas quinonas 3a-c, isoméricas de elipticina, y sus actividades antiproliferativas in vitro en líneas de células de cáncer. Las quinonas N-heterocíclicas 3a-c se sintetizaron a través de una secuencia que involucra: a) preparación de 4- metoxicarbonil-3,4-dimetlisoquinolin-5,8-quinone 1 a partir de 2,5-dihidroxiacetofenona, aminocrotonato de metilo y óxido de plata (I); b) aminación regioselectiva de 1 con arilaminas para producir las aminoquinonas 2a-c y c) acoplamiento oxidante intramolecular de 7- aminoisoquinolin-5,8-quinonas 2a-c catalizado con paladio. La actividad antiproliferative in vitro de los nuevos compuestos fue evaluada en una línea celular normal (fibroblastos de pulmón) y líneas de células de cáncer gástrico, pulmón y vejiga en ensayos de exposición de 72 horas a la droga. Las quinonas 3a-c exhiben interesantes propiedades antiproliferativas destacando la elipticinquinona isomérica 2b en células de cáncer de vejiga (IC50: 2.4 uM) comparado con etopósido usada como droga anticancer de referencia. Los nuevos compuestos mostraron actividades antiproliferativa similar o mayor respecto de las correspondientes quinonas precursoras 2a-c. La elipticin quinona isomérica 2b corresponde al miembro más activo en células de câncer de vejiga (IC50: 2.4 uM), comparable a la del etopósido, usada como droga anticáncer de referencia...


Asunto(s)
Humanos , Elipticinas/farmacología , Elipticinas/síntesis química , Proliferación Celular , Quinonas/farmacología , Quinonas/síntesis química , Línea Celular Tumoral , Acoplamiento Oxidativo
2.
Southeast Asian J Trop Med Public Health ; 2000 Mar; 31(1): 118-22
Artículo en Inglés | IMSEAR | ID: sea-31874

RESUMEN

Vaginal trichomoniasis is a highly prevalent sexually transmitted disease caused by a microaerophilic protozoan Trichomonas vaginalis. The disease is one of the most common sexually transmitted disease and can augment the predisposition of individuals to human immunodeficiency virus (HIV) infection. Although the disease can be treated with metronidazole and related 5-nitroimidazole, cases of trichomonal vaginitis which are refractory to standard treatment seems to be increasing. Clearly, new antitrichomonad agents are needed and DNA topoisomerase II may acts as a new target for antitrichomonad agents. In this study, in vitro sensitivity of T. vaginalis to DNA topoisomerase II was investigated. Axenic culture of local strain of T. vaginalis was performed. Both eukaryotic and prokaryotic DNA topoisomerase II inhibitors such as ellipticine, amsacrine and fluoroquinolones were tested for effectiveness against T. vaginalis in vitro compared to metronidazole. T. vaginalis was sensitive to metronidazole under aerobic conditions. Minimal inhibitory concentrations (MICs) of eukaryotic DNA topoisomerase II inhibitors, ellipticine and amsacrine, were 6.4 mM and 64 mM, respectively. The MICs of prokaryotic DNA topoisomerase II or DNA gyrase inhibitors; ciprofloxacin, ofloxacin and norfloxacin were 64, 960 and 1,280 mM, respectively. Based on the results, among DNA topoisomerase II inhibitors ellipticine was the most effective drug against T. vaginalis in vitro whereas fluoroquinolones did not show high antitrichomonad activity.


Asunto(s)
Amsacrina/farmacología , Animales , Antiinfecciosos/farmacología , Antitricomonas/farmacología , ADN-Topoisomerasas de Tipo II/antagonistas & inhibidores , Elipticinas/farmacología , Inhibidores Enzimáticos/farmacología , Fluoroquinolonas , Metronidazol/farmacología , Pruebas de Sensibilidad Parasitaria , Trichomonas vaginalis/efectos de los fármacos
3.
Ciênc. cult. (Säo Paulo) ; 49(5/6): 370-7, Sept.-Dec. 1997. tab, graf
Artículo en Inglés | LILACS | ID: lil-214099

RESUMEN

Several derivatives of well-known natural anticancer drugs have been synthesized and will continue to be, to overcome their delivering problems, or effectiveness. Characteristics such as poor solubility, metabolic inactivation, resistance development, rapid clearance or short half-life, adverse side effects like nausea, alopecia, anorexia are common undesirable limitations to their clinical use. Drug toxicity to less sensitive tumors as those in liver or brain is another aimed goal. Recent efforts to reverse undesirable physicochemical properties of well-established natural anticancer compounds are focused. Improved antitumor action of olivacine in L(1210) leukemia with slightly soluble halides with increased life span as well as "cured" animals was observed.


Asunto(s)
Humanos , Antineoplásicos Fitogénicos/farmacología , Elipticinas/farmacología , Leucemia L1210/tratamiento farmacológico , Antineoplásicos Fitogénicos/uso terapéutico , Elipticinas/uso terapéutico , Supervivencia Celular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA